Supplementary Table e-1. Cumulative incidence of MCI in the 5 years following baseline assessment, obtained in groups defined by quartiles of the cross-validated risk score from the augmented clinical model that included APOE ε4 carrier status. Estimates are shown as percentages,

and were obtained while accounting for the competing risk of death for the selected baseline ages for men and women.

| | | - | | alative incidence of | f MCI | |
|----------------|---------|----------|----------|----------------------|--------------|---------|
| Woman, age 70 | | 1 year | 2 years | 3 years | 4 years | 5 years |
| Risk score | < 38 | 0.5 | 1 | 1.1 | 2.2 | 3.4 |
| | 38 – 49 | 1.1 | 2 | 2.3 | 4.5 | 6.9 |
| | 50 – 62 | 2.1 | 3.6 | 4.2 | 8.1 | 12.4 |
| | 63+ | 3.6 | 6.2 | 7.1 | 13.5 | 20.2 |
| | | | | | | |
| Woman, age 75 | | 1 year | 2 years | 3 years | 4 years | 5 years |
| Risk score | < 38 | 0.8 | 1.5 | 1.7 | 3.4 | 5.2 |
| | 38 – 49 | 1.8 | 3.1 | 3.5 | 6.8 | 10.4 |
| | 50 – 62 | 3.3 | 5.6 | 6.4 | 12.1 | 18.1 |
| | 63+ | 5.5 | 9.4 | 10.7 | 19.8 | 28.9 |
| 11 7 00 | | 1 | 2 | 2 | 4 | |
| Woman, age 80 | . 20 | 1 year | 2 years | 3 years | 4 years | 5 years |
| Risk score | < 38 | 1.8 | 3.2 | 5 | 8.8 | 12.6 |
| | 38 – 49 | 3.7 | 6.5 | 10.1 | 17.2 | 24.1 |
| | 50 – 62 | 6.8 | 11.7 | 17.9 | 29.2 | 39 |
| | 63+ | 11.4 | 19.1 | 28.6 | 44.6 | 57.1 |
| Woman, age 85 | | 1 year | 2 years | 3 years | 4 years | 5 years |
| Risk score | < 38 | 2.8 | 4.9 | 7.7 | 13.1 | 18.5 |
| | 38 – 49 | 5.8 | 9.8 | 15.1 | 24.7 | 33.1 |
| | 50 - 62 | 10.4 | 17.3 | 25.9 | 39.6 | 49.8 |
| | 63+ | 17.1 | 27.8 | 40.1 | 57.9 | 69 |
| Man. 252 70 | | 1 ****** | 2 112000 | 2 | 4 220000 | 5 |
| Man, age 70 | < 27 | 1 year | 2 years | 3 years | 4 years | 5 years |
| Risk score | 18 – 38 | 1.4 | 2.4 | 3.2 | 4.5 | 6.3 |
| | 39 – 53 | 2.9 | 4.9 | 6.6 | 9.1 | 12.5 |
| | | 5.3 | 8.9 | 11.8 | 16.2 | 21.6 |
| | 54+ | 8.8 | 14.7 | 19.3 | 26 | 34.1 |
| Man, age 75 | | 1 year | 2 years | 3 years | 4 years | 5 years |
| Risk score | < 27 | 2.2 | 3.7 | 4.9 | 6.9 | 9.4 |
| | 18 – 38 | 4.5 | 7.5 | 9.9 | 13.6 | 18.2 |
| | 39 – 53 | 8.1 | 13.4 | 17.5 | 23.4 | 30.2 |
| | 54+ | 13.4 | 21.8 | 28 | 36.6 | 46.1 |
| Man, age 80 | | 1 2000 | 2 1/2000 | 2 112000 | 4 110 0 110 | 5 |
| Risk score | < 27 | 1 year | 2 years | 3 years 4.6 | 4 years 7 | 5 years |
| KISK SCOIE | 18 – 38 | 2.4 | 8 | 9.2 | | 9.5 |
| | | 4.8 | | | 13.8 | 18.3 |
| | 39 – 53 | 8.8 | 14.3 | 16.3 | 23.6 | 30.1 |
| | 54+ | 14.5 | 23.1 | 26.2 | 36.9 | 46 |
| Man, age 85 | | 1 year | 2 years | 3 years | 4 years | 5 years |
| Risk score | < 27 | 3.6 | 6 | 7 | 10.4 | 12.5 |
| | 18 – 38 | 7.4 | 12 | 13.7 | 19.7 | 25.8 |
| | 39 – 53 | 13.4 | 20.7 | 23.4 | 31.9 | 36.9 |
| | 54+ | 21.7 | 32.9 | 36.7 | 48.4 | 60.1 |